Novo Holdings

Commit Biologics is a biotechnology research company based in Aarhus, Denmark, established in 2021. The company specializes in developing an innovative immunotherapy platform aimed at treating various types of cancer. This platform utilizes bispecific domain antibodies to effectively target and eliminate tumor cells. Furthermore, it incorporates modular technology that enhances its ability to engage the body's innate immune response, thereby activating the complement component of the immune system. This approach not only focuses on cancer treatment but also has potential applications in addressing autoimmune diseases.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

Convergent Therapeutics is a clinical-stage biotechnology company specializing in the development of radiopharmaceutical therapies for prostate cancer. The company's lead product, CONV 01-α, is a monoclonal antibody conjugated with the radioactive alpha particle emitter 225Ac, designed to bind specifically to the prostate-specific membrane antigen (PSMA). This innovative therapy allows for the internalization of the radioactive payload directly into prostate cancer cells, enhancing treatment efficacy. Developed through proprietary technology by Dr. Neil Bander at Weill Cornell Medicine, CONV 01-α is protected by multiple U.S. and foreign patents. If it receives FDA approval, it will become the first antibody to target a radioisotope for prostate cancer treatment and the first drug to utilize 225Ac in this context. Convergent Therapeutics aims to leverage its therapeutic platform to explore targeted combination strategies against validated and novel cancer antigens, ultimately enhancing treatment options for patients.

Commit Biologics is a biotechnology research company based in Aarhus, Denmark, established in 2021. The company specializes in developing an innovative immunotherapy platform aimed at treating various types of cancer. This platform utilizes bispecific domain antibodies to effectively target and eliminate tumor cells. Furthermore, it incorporates modular technology that enhances its ability to engage the body's innate immune response, thereby activating the complement component of the immune system. This approach not only focuses on cancer treatment but also has potential applications in addressing autoimmune diseases.

HPNow is a company focused on developing innovative water and air treatment solutions through the on-site generation of hydrogen peroxide. Their technology allows for the efficient and autonomous production of hydrogen peroxide using only water, electricity, and air. With their compact HPGen hydrogen-peroxide generators, HPNow aims to replace conventional disinfectants, such as chlorine, which are increasingly regulated due to safety concerns. This transition not only enhances the safety of water, air, and food but also offers significant cost savings and logistical benefits for users. By providing a safer and eco-friendly alternative to toxic chemical disinfectants, HPNow seeks to reduce environmental impact while improving overall treatment efficacy across various industries.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Engimmune Therapeutics is a biotechnology company focused on developing innovative T cell receptor (TCR) therapies aimed at treating solid tumors. The company leverages advanced life sciences technologies, including genome editing, functional high-throughput screening, deep sequencing, and machine learning, to create highly potent and specific immunotherapies. By addressing critical efficacy and safety challenges in cancer treatment, Engimmune Therapeutics is dedicated to providing effective solutions for patients suffering from serious diseases with significant unmet medical needs.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

The Ritedose Corporation is a specialized pharmaceutical contract manufacturer based in Columbia, South Carolina. Founded in 1995, the company provides blow-fill-seal (BFS) manufacturing services for small fill volume pharmaceutical unit dose sterile and non-sterile liquids. Its product offerings include inhalation vials, eye drops, ear drops, and oral liquids, with a particular emphasis on unit dose nebulized liquids for the respiratory market, such as albuterol and ipratropium. The Ritedose is recognized for its expertise in aseptic manufacturing and liquid packaging, catering to the needs of clients seeking efficient, consistent, and safe dosage delivery. The company was previously known as Holopack International Corp. until it was renamed in March 2009 following its acquisition by Olympus Partners.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, enabling the production of functional proteins in the bloodstream. Freeline's pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, the company offers expertise in CMC process development, analytics, and AAV technologies.

Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for treating various cancers and autoimmune diseases. Unlike T-cell therapies, NK cells have an inherent ability to recognize and destroy abnormal cells without genetic alteration, offering promise for diverse tumor types with potentially better tolerated side effects. Nkarta's approach involves leveraging its NK expansion platform technology alongside proprietary cell engineering techniques to generate a substantial supply of enhanced NK cells that can persistently target and eliminate cancer cells.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in the research, development, and manufacturing of lentiviral vector and cell therapy products for various diseases. The company operates through two main segments: Platform and Product. Its LentiVector platform technology enables the integration of therapeutic genes into non-dividing cells, making it suitable for treating conditions affecting the brain and eyes. Oxford BioMedica's product pipeline includes several candidates in various stages of development, targeting diseases such as hematological tumors, age-related macular degeneration, and central nervous system disorders. Additionally, the company has established partnerships with notable firms like Novartis and Bristol Myers Squibb to advance its therapeutic offerings. Oxford BioMedica also focuses on growing its bioprocessing services, leveraging its technologies to provide revenue-generating solutions for third-party clients, while continuing to innovate in gene and cell therapy. Founded in 1995, the company has positioned itself as a leader in the field of gene therapy, addressing unmet medical needs through its advanced therapeutic candidates.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in the research, development, and manufacturing of lentiviral vector and cell therapy products for various diseases. The company operates through two main segments: Platform and Product. Its LentiVector platform technology enables the integration of therapeutic genes into non-dividing cells, making it suitable for treating conditions affecting the brain and eyes. Oxford BioMedica's product pipeline includes several candidates in various stages of development, targeting diseases such as hematological tumors, age-related macular degeneration, and central nervous system disorders. Additionally, the company has established partnerships with notable firms like Novartis and Bristol Myers Squibb to advance its therapeutic offerings. Oxford BioMedica also focuses on growing its bioprocessing services, leveraging its technologies to provide revenue-generating solutions for third-party clients, while continuing to innovate in gene and cell therapy. Founded in 1995, the company has positioned itself as a leader in the field of gene therapy, addressing unmet medical needs through its advanced therapeutic candidates.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, specializing in the development of immuno-oncology therapies. The company focuses on creating first-in-class agents that modulate the immune system to treat cancer and other diseases. Its lead product candidate, Ciforadenant (CPI-444), is an oral small molecule antagonist of the A2A receptor currently undergoing Phase Ib/2 clinical trials. Additionally, Corvus is developing CPI-006, an anti-CD73 monoclonal antibody in Phase I/Ib trials aimed at inhibiting adenosine production and stimulating immune cells, as well as a Phase I trial for COVID-19. Another candidate, CPI-818, is a small molecule inhibitor targeting interleukin-2-inducible T-cell kinase, also in Phase I/Ib trials. The company has established a strategic collaboration with Angel Pharmaceuticals to further advance its pipeline of investigational medicines. Founded in 2014, Corvus Pharmaceuticals aims to contribute significantly to the field of immunotherapy and improve patient outcomes in various diseases.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for treating various cancers and autoimmune diseases. Unlike T-cell therapies, NK cells have an inherent ability to recognize and destroy abnormal cells without genetic alteration, offering promise for diverse tumor types with potentially better tolerated side effects. Nkarta's approach involves leveraging its NK expansion platform technology alongside proprietary cell engineering techniques to generate a substantial supply of enhanced NK cells that can persistently target and eliminate cancer cells.

Pulmologix AB is a clinical stage company based in Stockholm, Sweden, that specializes in developing and manufacturing innovative treatments for respiratory diseases, particularly focusing on early onset allergic asthma. Founded in 2006, the company is dedicated to advancing oral non-steroidal anti-asthmatic drugs aimed at improving patient outcomes in asthma management. Through its research and development efforts, Pulmologix seeks to explore new medical approaches that address unmet needs in respiratory care.

Lysogene S.A. is a biotechnology company based in Neuilly-sur-Seine, France, focused on the research and clinical development of gene therapy for neurodegenerative disorders. Founded in 2009, the company is advancing several clinical programs, including LYS-SAF302, currently in Phase II/III trials for the treatment of mucopolysaccharidosis type IIIA, and LYS-GM101, which is in Phase I/II trials for GM1 gangliosidosis. Lysogene is also engaged in a collaborative research effort with the Weizmann Institute of Science to develop a novel AAV gene therapy approach targeting neuronopathic Gaucher disease, Parkinson's disease, and other conditions. The company aims to enhance the health outcomes of patients suffering from life-threatening, incurable disorders by utilizing AAV vectors that effectively deliver genetic material to the central nervous system.

Ceterix Orthopaedics, Inc. is a medical technology company that specializes in developing innovative surgical tools for arthroscopic procedures. Founded in October 2010 and based in Fremont, California, Ceterix offers the NovoStitch® Plus Meniscal Repair System, designed to address complex meniscal tears, including horizontal, radial, and root tears. The company also provides the Novocut Suture Manager, a device that facilitates efficient suture management. Ceterix's technology enables orthopedic surgeons to create intricate suture patterns in tight joint compartments while safeguarding surrounding structures, such as nerves and cartilage. This advancement allows for improved outcomes in arthroscopic procedures across various joints, including the knees, hips, and shoulders. Ceterix was previously known as SuturePro Technologies, Inc. before rebranding in April 2011 and is currently a subsidiary of Smith & Nephew plc.

Alios BioPharma is focused on discovering and developing innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company utilizes a range of proprietary platform technologies, including small molecule activators of innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons. These technologies enable the development of distinct therapeutic products targeting serious viral conditions such as chronic hepatitis B and C, HIV, and respiratory viruses, including pandemic influenza and emerging diseases like SARS. Alios BioPharma's approach is supported by a proprietary chemical library of nucleoside analogs and advanced virology-based screening systems, positioning the company as a key player in the field of antiviral therapeutics.

Avilex Pharma is a biotechnology company based in Copenhagen, Denmark, founded in 2012 as a spin-out from the University of Copenhagen. The company specializes in developing innovative treatments for neuropathic pain and ischemic stroke. Its research focuses on dimeric peptides that target PSD95, a postsynaptic density protein, as well as inhibitors and neuroprotectants aimed at the intracellular scaffolding protein. Avilex Pharma's mission is to enhance patient recovery and outcomes in these critical areas of healthcare, leveraging advanced drug design and pharmacology techniques developed by its founders, Professor Kristian Strømgaard and Assistant Professor Anders Bach.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

Inogen is a medical technology company specializing in oxygen therapy solutions for patients with chronic respiratory conditions. The company designs and manufactures portable oxygen concentrators, with its flagship product being the Inogen One system, which offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen sells its products to home medical equipment providers and directly rents devices to patients, primarily generating its revenue in the United States. Additionally, the company distributes its products internationally through partnerships with large gas companies and home oxygen providers. Inogen's mission is to enhance the freedom and independence of oxygen therapy users by providing innovative and user-friendly products and services.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Alios BioPharma is focused on discovering and developing innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company utilizes a range of proprietary platform technologies, including small molecule activators of innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons. These technologies enable the development of distinct therapeutic products targeting serious viral conditions such as chronic hepatitis B and C, HIV, and respiratory viruses, including pandemic influenza and emerging diseases like SARS. Alios BioPharma's approach is supported by a proprietary chemical library of nucleoside analogs and advanced virology-based screening systems, positioning the company as a key player in the field of antiviral therapeutics.

Alios BioPharma is focused on discovering and developing innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company utilizes a range of proprietary platform technologies, including small molecule activators of innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons. These technologies enable the development of distinct therapeutic products targeting serious viral conditions such as chronic hepatitis B and C, HIV, and respiratory viruses, including pandemic influenza and emerging diseases like SARS. Alios BioPharma's approach is supported by a proprietary chemical library of nucleoside analogs and advanced virology-based screening systems, positioning the company as a key player in the field of antiviral therapeutics.

Alios BioPharma is focused on discovering and developing innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company utilizes a range of proprietary platform technologies, including small molecule activators of innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons. These technologies enable the development of distinct therapeutic products targeting serious viral conditions such as chronic hepatitis B and C, HIV, and respiratory viruses, including pandemic influenza and emerging diseases like SARS. Alios BioPharma's approach is supported by a proprietary chemical library of nucleoside analogs and advanced virology-based screening systems, positioning the company as a key player in the field of antiviral therapeutics.

EpiTherapeutics is a biotechnology company focused on developing innovative cancer therapies that leverage the science of epigenetics. Founded on research conducted by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre at the University of Copenhagen, the company specializes in small-molecule therapies targeting enzymes that regulate transcription in cancer cells. EpiTherapeutics has created a library of selective small molecule inhibitors, with a particular emphasis on histone demethylases, which play a critical role in gene transcription. The company's lead compounds are currently in pre-clinical development, aimed at addressing specific types of cancer.

Inogen is a medical technology company specializing in oxygen therapy solutions for patients with chronic respiratory conditions. The company designs and manufactures portable oxygen concentrators, with its flagship product being the Inogen One system, which offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen sells its products to home medical equipment providers and directly rents devices to patients, primarily generating its revenue in the United States. Additionally, the company distributes its products internationally through partnerships with large gas companies and home oxygen providers. Inogen's mission is to enhance the freedom and independence of oxygen therapy users by providing innovative and user-friendly products and services.